What is the Papillon treatment for rectal cancer?

Papillon is a low-energy X-ray therapy that delivers radiation directly to rectal tumours via a tube inserted through the anus, offering a non-surgical alternative.

Can Papillon treatment help avoid a stoma?

Yes, a major benefit of the Papillon treatment is that it can help rectal cancer patients avoid the need for a stoma, significantly improving their quality of life.

Who is eligible for the Papillon treatment in the NHS?

The Papillon treatment is recommended for fit rectal cancer patients with tumours 3cm or smaller, or those at high risk for surgery, with potential eligibility for larger tumours if reduced by other treatments.

Home / Health / New X-ray Therapy Spares Rectal Cancer Patients Stoma

New X-ray Therapy Spares Rectal Cancer Patients Stoma

2 Dec

•

Summary

Low-energy X-ray treatment approved for NHS use.
Papillon therapy allows rectal cancer patients to avoid stomas.
Treatment offers a better quality of life for patients.

New X-ray Therapy Spares Rectal Cancer Patients Stoma

A groundbreaking low-energy X-ray treatment for rectal cancer, known as Papillon, has recently gained approval for use within the National Health Service. This innovative therapy provides a viable non-surgical option for patients, potentially eliminating the necessity of a stoma, which significantly enhances their quality of life.

The Papillon treatment involves inserting an X-ray tube through the anus to deliver precise radiation doses directly to cancerous tumours. It is specifically recommended for patients with rectal tumours measuring 3cm or smaller, or those who choose to avoid surgery due to high risk. Pioneers of the technique, like Professor Sun Myint, have been using it for over three decades, with trials demonstrating remarkable success in preserving organs.

This NHS approval is hailed as a major victory for patient choice and well-being. Beyond improving individual lives, the widespread adoption of Papillon is expected to reduce surgical waiting lists and healthcare costs. Colorectal cancer, a common malignancy in the UK, will now benefit from this advanced treatment option, offering hope and better outcomes to many.